Detalhe da pesquisa
1.
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 99(4): 523-533, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38247315
2.
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Cancer
; 129(16): 2491-2498, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37282609
3.
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
Blood
; 123(1): 78-85, 2014 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24144643
4.
CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.
Blood
; 124(13): 2051-60, 2014 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25061178
5.
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.
Genes Chromosomes Cancer
; 54(11): 692-701, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26220195
6.
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Cancer Cell
; 12(2): 115-30, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17692804
7.
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.
Blood
; 119(2): 503-12, 2012 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22072558
8.
Prediction of cytogenetic abnormalities with gene expression profiles.
Blood
; 119(21): e148-50, 2012 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-22496154
9.
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
Cancer Cell
; 9(4): 313-25, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16616336
10.
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
Blood Adv
; 8(3): 703-707, 2024 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052037
11.
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
J Clin Invest
; 134(1)2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37883186
12.
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing.
Blood Cancer J
; 14(1): 38, 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38443358
13.
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
Cancers (Basel)
; 16(6)2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539451
14.
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Nat Commun
; 15(1): 615, 2024 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38242888
15.
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
J Exp Med
; 204(4): 831-40, 2007 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-17389240
16.
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
Br J Haematol
; 162(2): 210-20, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23647456
17.
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Blood
; 118(13): 3512-24, 2011 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-21628408
18.
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.
Proc Natl Acad Sci U S A
; 107(17): 7904-9, 2010 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-20385818
19.
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Blood Adv
; 7(13): 3069-3074, 2023 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36857755
20.
Variability of definition of high-risk multiple myeloma across phase III clinical trials.
EJHaem
; 4(2): 454-458, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37206288